DECIPHERA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.23 USD | -3.33% |
|
-8.31% | -11.78% |
Chart calendar Deciphera Pharmaceuticals, Inc.
097d.w7OGVQXijK_Fu9e5gpyCi3iE8_t6HhL3K73QI0DCUII.mve0IWDb582r1JHf8Mja3gvUsJ4vK0WQfIy9FgG7KNL34dY6coTN9pHxjg~a13f677592b84c7db9acb57af4e2665d
Upcoming events on Deciphera Pharmaceuticals, Inc.
Past events on Deciphera Pharmaceuticals, Inc.
| 2024-04-16 11:30 am | Stifel Virtual Targeted Oncology Days Conference |
| 2024-03-13 08:00 am | Barclays Global Healthcare Conference |
| 2024-03-11 02:40 pm | Leerink Partners Global Biopharma Conference |
| 2024-03-05 01:30 pm | TD Cowen Health Care Conference |
| 2024-02-08 09:00 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 2024-02-06 08:00 am | Q4 2023 Earnings Call |
| 2024-02-06 07:00 am | Q4 2023 Earnings Release |
| 2024-01-18 02:45 pm | American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Abstract No - 748 |
| 2024-01-09 07:30 pm | JPMorgan Healthcare Conference |
| 2023-12-06 01:30 pm | JMP Securities Hematology and Oncology Summit |
| 2023-11-29 12:00 pm | Piper Sandler Healthcare Conference |
| 2023-11-15 01:50 pm | Stifel Healthcare Conference |
| 2023-11-14 11:00 am | Jefferies London Healthcare Conference |
| 2023-10-30 08:00 am | Q3 2023 Earnings Call - Vimseltinib Phase 3 Study Results Call |
| 2023-10-30 07:01 am | Q3 2023 Earnings Release |
| 2023-08-09 08:00 am | Q2 2023 Earnings Call |
| 2023-08-09 07:00 am | Q2 2023 Earnings Release |
| 2023-06-21 08:30 am | Annual General Meeting |
| 2023-06-08 02:30 pm | Jefferies Global Healthcare Conference |
| 2023-06-03 02:54 pm | American Society of Clinical Oncology Conference - Abstract Number: 397784 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 25,0 24,1 3.77% | 42,1 41,1 2.45% | 96,1 95,3 0.89% | 134 133 0.53% | 163 162 0.93% | 200 |
|
EBITDA Million USD | Released Forecast Spread | -200 -191 -4.54% | -269 -272 1.16% | -297 -304 2.33% | -180 -173 -3.92% | -209 -213 1.85% | -202 |
|
EBIT Million USD | Released Forecast Spread | -201 -190 -5.72% | -271 -276 1.61% | -300 -299 -0.46% | -183 -180 -1.53% | -211 -214 1.61% | -206 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -192 -182 -5.38% | -266 -269 0.77% | -300 -308 2.52% | -178 -177 -0.56% | -195 -199 2.06% | -186 |
|
Net income Million USD | Released Forecast Spread | -192 -183 -5.3% | -266 -270 1.18% | -300 -298 -0.52% | -179 -177 -0.92% | -195 -199 1.99% | -195 |
|
EPS USD | Released Forecast Spread | -4,48 -4,15 -7.9% | -4,78 -4,84 1.33% | -5,16 -5,13 -0.54% | -2,37 -2,48 4.44% | -2,29 -2,34 2.14% | -2,16 |
| Announcement Date | 09/03/20 | 09/02/21 | 08/02/22 | 07/02/23 | 06/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 24,2 23,3 3.93% | 29,2 27,2 7.55% | 32,5 30,1 7.93% | 36,0 33,0 8.98% | 36,3 35,9 1.3% | 33,4 35,5 -5.78% | 38,3 36,3 5.47% | 43,3 39,2 10.42% | 48,3 46,8 3.19% | 46,2 | 48,9 | 52,7 | 53,6 | 48,6 |
|
EBITDA Million USD | Released Forecast Spread | -87,6 -95,0 7.77% | -46,1 -64,0 27.95% | -43,0 -46,0 6.59% | -44,1 -42,0 -5.09% | -46,6 -40,0 -16.4% | -52,6 -50,0 -5.3% | -50,8 -55,0 7.67% | -50,0 | -49,0 | -50,0 | -53,0 | |||
|
EBIT Million USD | Released Forecast Spread | -88,4 -87,0 -1.63% | -46,9 -50,2 6.62% | -43,8 -46,1 5.08% | -44,9 -44,2 -1.56% | -47,2 -44,5 -6.03% | -53,3 -49,0 -8.75% | -52,8 -52,7 -0.12% | -53,7 -54,8 2.08% | -51,2 -54,3 5.68% | -51,4 | -51,6 | -50,9 | -51,9 | -48,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -88,4 -96,0 7.95% | -46,9 -52,8 11.27% | -43,1 -45,8 6.05% | -43,0 -44,2 2.56% | -45,2 -44,2 -2.29% | -49,6 -48,6 -2.08% | -48,6 -51,2 5.17% | -49,6 -51,9 4.39% | -46,8 -49,5 5.54% | -47,5 | -46,9 | -46,0 | -47,3 | -44,1 |
|
Net income Million USD | Released Forecast Spread | -88,4 -86,8 -1.88% | -46,9 -50,2 6.56% | -43,1 -45,4 5.2% | -43,0 -43,7 1.46% | -45,9 -44,1 -4.2% | -49,6 -48,9 -1.55% | -48,6 -52,2 6.96% | -49,6 -52,4 5.4% | -47,2 -50,2 6.04% | -48,5 | -48,7 | -48,5 | -49,8 | -44,1 |
|
EPS USD | Released Forecast Spread | -1,51 -1,48 -2.02% | -0,80 -0,85 6.07% | -0,60 -0,66 8.55% | -0,55 -0,58 5.17% | -0,60 -0,56 -7.36% | -0,60 -0,59 -1.11% | -0,57 -0,62 8.43% | -0,58 -0,62 5.69% | -0,54 -0,58 7.1% | -0,55 | -0,55 | -0,52 | -0,54 | -0,46 |
| Announcement Date | 08/02/22 | 04/05/22 | 04/08/22 | 03/11/22 | 07/02/23 | 03/05/23 | 09/08/23 | 30/10/23 | 06/02/24 | - | - | - | - | - |
More events
Past sector events for Deciphera Pharmaceuticals, Inc.
| 2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- DCPH Stock
- Calendar Deciphera Pharmaceuticals, Inc.
